Pfizer drug shows promise in lung cancer-study - Reuters

Wall Street Journal

Pfizer drug shows promise in lung cancer-study Reuters * Dacomitinib "median progression free survival" was 17 months * 74 pct of patients had partial response to drug May 16 (Reuters) - An experimental lung cancer pill being developed by Pfizer Inc showed promise in delaying worsening of the disease, ... Pfizer Lung Drug Stops Deadly Child Cancers in StudyBloomberg Lung cancer drug treats rare lymphoma tumors, toomsnbc.com (blog) Pfizer adult lung cancer drug Xalkori shows promise with childhood tumorsFOX 4 News Chicago Tribune -Wall Street Journal all 44 news articles »

Lung Cancer Alliance Announces Important First Step Cleared For More Federal ... - Sacramento Bee

IBTimes.co.uk

Lung Cancer Alliance Announces Important First Step Cleared For More Federal ... Sacramento Bee But inclusion of lung cancer funding at this stage of the process is a significant development and signals that the program remains strongly endorsed. "Securing increased federal research funding for all aspects of lung cancer has been, ... Cancer Research UK to investigate new drug combination in lung cancerHealthCanal.com Study: Video-assisted surgery, CT lung cancer screening go hand-in-handHealth Imaging Video-assisted thoracic surgery valuable tool in lung cancer screeningEurekAlert (press release) IBTimes.co.uk all 20 news articles »

Array shares rise on lung cancer, melanoma results - Reuters

Array shares rise on lung cancer, melanoma results Reuters Array, which has licensed the lung cancer drug to AstraZeneca Plc, announced last year that a mid-stage trial had failed to meet its main goal of showing statistically significant improvement in overall survival. The full trial results -- released ... Synta Announces Presentations at the 2012 American Society for Clinical ...MarketWatch (press release) ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)TheStreet.com 48th Annual Meeting of the American Society of Clinical Oncology (ASCO): Bayer ...Sacramento Bee SunHerald.com all 53 news articles »

Myriad Genetics Announces Presentation of Lung Cancer Study at American ... - MarketWatch (press release)

Myriad Genetics Announces Presentation of Lung Cancer Study at American ... MarketWatch (press release) Researchers at MD Anderson Cancer Center and Myriad Genetics generated a cell cycle progression (CCP) score for 256 patients with stage I and II lung adenocarcinoma by analyzing the level of expression in 46 cell-cycle progression and housekeeping ... and more »

Boehringer Ingelheim to present pivotal Phase III results for afatinib in ... - MarketWatch (press release)

Boehringer Ingelheim to present pivotal Phase III results for afatinib in ... MarketWatch (press release) RIDGEFIELD, Conn., May 16, 2012 /PRNewswire via COMTEX/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer ... Pivotal study on afatinib may challenge current standard first line treatment1 ...National Post Results from Boehringer Ingelheim's LUX-Lung 3 Phase III trial on stage IIIB ...News-Medical.net Boehringer Ingelheim reports positive data for lung cancer therapyZenopa all 7 news articles »